Navigation Links
New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
Date:6/23/2008

BETHLEHEM, Pa., June 23 /PRNewswire/ -- A new blood test may make it easier for oncologists to accurately measure and personalize 5-fluorouracil (5-FU) dosing for patients undergoing continuous infusion chemotherapy regimens. Data from a multicenter trial showed that a nanoparticle-based immunoassay from Saladax Biomedical, called 5-FU Personalized Chemotherapy Management (PCM(R)), performed as well as high performance liquid chromatography (HPLC) or LC-MS/MS, but was easier to use, more rapid and more amenable to widespread clinical use. The data was presented at the 2008 Hematology/Oncology Pharmacy Association and the International Society of Oncology Pharmacy Practitioners' (HOPA/ISOPP) annual meeting in Anaheim, Calif.

5-FU is a cornerstone treatment regimen for colorectal cancer; the third leading cause of cancer deaths in the United States.(i)

"This evidence-based tool for monitoring the actual drug concentrations of 5-FU in the blood will enable simplified, personalized dose management with the goal of minimizing toxicity and maximizing the therapeutic benefit of 5-FU treatment," said Salvatore Salamone, Ph.D., CEO of Saladax Biomedical. "This is important because a significant amount of scientific evidence over the last decade demonstrates that the effectiveness of the 5-FU regimen is burdened by potentially severe and life-threatening side effects."

To date, analysis of 5-FU blood plasma levels could only be performed by complex, labor-intensive, expensive, and physical analytical methods such as HPLC that have insufficient capacity to be used in high volume clinical settings. The 5-FU PCM assay could provide the same HPLC or LC-MS/MS-like performance, while offering advantages of automation, small sample size, and improved turn-around time for oncologists.

The multicenter study evaluated 5-FU blood plasma levels at three sites, according to the Clinical and Laboratory Standards Institute (CLSI) protocol. 5-FU blood plasm
'/>"/>

SOURCE Saladax Biomedical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
2. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
3. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
4. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
5. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
6. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
9. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
10. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
11. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 2014 Research and Markets ( ... "Drug Injection Devices to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs become ... of health conditions, drug developers have increasingly pursued ... process and increase the efficiency and reliability with ...
(Date:12/13/2014)... 12, 2014 HudsonAlpha Institute for Biotechnology ... Ten sequencing system manufactured by Illumina, Inc. (NASDQ: ... and analyze genomic data faster and at a ... commitment to research programs for genomics excellence in ... provides unprecedented capacity, speed and accuracy for sequencing ...
(Date:12/13/2014)... and INDIANAPOLIS , Dec. 12, 2014 /PRNewswire/ ... Ganassi Racing Teams (CGRT), today announced a multi-year extension of ... sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing ... IndyCar Series. Kimball, 29, from ... driver with diabetes in the history of INDYCAR to win ...
Breaking Medicine Technology:Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7
(Date:12/17/2014)... Alan Mozes HealthDay ... With the holiday party season fast approaching, a new study ... make DUI arrests have fewer drunk drivers on their roads. ... laws more vigilantly are better able to deter inebriated revelers ... "Hardly any new laws are being passed regarding drinking and ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... December 15, 2014 Health Dialog, ... announced today that it has received Patient Oriented ... (NCQA) for its Disease Management (DM) Programs for ... (COPD), coronary heart disease and diabetes. This marks ... for Health Dialog’s Disease Management (DM) Programs, reaffirming ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device regulatory consulting ... South America, Europe, the Middle East, Asia and Australia, ... 2015 Medical Device Industry Survey. Each year, Emergo conducts ... market trends as well as regulatory and operational concerns ... , Overall prospects for medical device ...
(Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Popular ,Out of the Closet, Thrift Store, Non-profit,AHF Pharmacy, ... Make a Difference, Grand Opening Event to Include ... This Saturday, February,2nd at 10:00 a.m., AIDS Healthcare ... Pharmacy, with a grand opening event to include,a ribbon-cutting ...
... enthused about Part D,s success, but critics say problems ... The three-year-old Medicare Part D drug program is seeing ... for the program fall, U.S. health officials announced Thursday. ... lower than originally projections, enrollment continues to rise and ...
... of the novel drug romiplostim (Nplate) show that it ... thrombocytopenic purpura (ITP), a hematologic disorder that can cause ... 3 trial results for the drug, which duplicates the ... General Hospital (MGH) investigator, in the February 2 issue ...
... International Associates, Inc.,administrator for the HealthShares(TM) Indexes, a ... Funds, today announced,that effective at the opening of ... BIM) will replace GYRUS GROUP PLC (GYG LN),in ... Companies that are included in The HealthShares(TM) ...
... in Karmanos Cancer Institute,s Annual Dinner, May 17, ... Karmanos,Cancer Institute will upgrade its nurse paging system, ... according to Nick Karmanos, vice,president of development for ... "As Lead Sponsor for our 26th Annual Dinner ...
... differences between nonprofit, for-profit banks should be explained , , ... tell pregnant patients considering umbilical cord blood banking about ... blood banks, new guidelines state. , The American College ... Opinion in the February issue of Obstetrics & ...
Cached Medicine News:Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 2Health News:West Hollywood: AHF Hosts Grand Opening of HIV/AIDS Pharmacy that Benefits AIDS Patients Worldwide 3Health News:Medicare's Drug Program Enrollment Up, Costs Down 2Health News:Medicare's Drug Program Enrollment Up, Costs Down 3Health News:Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder 2Health News:Ford Motor Company Fund Continues Longtime Support to Cancer Care 2Health News:Docs Should Tell All About Cord Blood Banks 2
... is a electronic medical records software for ... The Medical Office Records does more than ... designed to follow the flow of your ... previous encounters to establishing new examination records ...
... ChartMaker is a modular, Electronic Medical Record ... Windows to create a patient chart. ChartMaker ... E & M compliant patient notes, medical reports, ... template driven, ChartMaker is designed to be installed ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
Medicine Products: